Egypt’s Drug Authority, J&J explore deeper cooperation on pharma innovation

Egypt’s Drug Authority (EDA) held talks with Johnson & Johnson (J&J) on Tuesday to boost collaboration in pharmaceutical innovation, healthcare training, and accelerating the rollout of new treatments in Egypt, the Cabinet said in a statement.

EDA head Ali El-Ghamrawy met with the delegation to discuss streamlining regulatory pathways for Johnson & Johnson’s latest therapeutics, while enhancing joint training—particularly in health economics—to support Egypt’s Vision 2030 healthcare strategy.

El-Ghamrawy said the EDA is committed to working with leading global pharmaceutical firms to improve drug accessibility and foster innovation. He pointed to Egypt’s regulatory reforms and its growing appeal as a destination for pharmaceutical investment and production.

“The Egyptian pharmaceutical market is one of the region’s most promising,” El-Ghamrawy noted, citing the EDA’s alignment with international standards and its efforts to strengthen market competitiveness and patient access.

The Johnson & Johnson team, representing its Janssen pharmaceutical division, praised Egypt’s regulatory flexibility and reaffirmed its long-term commitment to making innovative therapies available to Egyptian patients. The company also voiced interest in expanding its footprint in Egypt as a regional hub for pharmaceutical manufacturing and exports.

The meeting is part of the EDA’s broader push to deepen partnerships with multinational pharmaceutical companies and position Egypt as a leading centre for medical innovation and regional drug production.

Attribution: Amwal Al Ghad English

Subediting: Y.Yasser